The importance of identifying and validating prognostic factors in oncology. - Wikidata - awgldk - TriplyDB

The importance of identifying and validating prognostic factors in oncology.

The importance of identifying and validating prognostic factors in oncology.

http://www.wikidata.org/entity/Q34090548

about

Special considerations in prognostic research in cancer involving genetic polymorphisms Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.On model specification and selection of the Cox proportional hazards model.Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.Identification of novel prognosis-related genes associated with cancer using integrative network analysis.

P2860

Q34775103-AED6A669-B6ED-4C79-9EE7-CDC36CC232B8 Q36953563-C5C87378-E14C-4D23-8BD9-DBE73B1DA341 Q37227787-9750B513-3E5F-419D-ACB4-0BDA9332363A Q37325001-0272FEBB-862C-45D9-8970-78CC152B1AEB Q38664856-1FF9AE9D-2E2C-4F1C-8AD5-16988EAF7689 Q42674196-B6A7FEC7-70CD-4D63-8FD6-E9730ECBA46D Q49830802-B840C972-F672-43B3-B29A-867C97C4454D

P2860

The importance of identifying and validating prognostic factors in oncology.

http://www.wikidata.org/entity/Q34090548

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The importance of identifying and validating prognostic factors in oncology.

@ast

The importance of identifying and validating prognostic factors in oncology.

@en

The importance of identifying and validating prognostic factors in oncology.

@nl

type

label

The importance of identifying and validating prognostic factors in oncology.

@ast

The importance of identifying and validating prognostic factors in oncology.

@en

The importance of identifying and validating prognostic factors in oncology.

@nl

prefLabel

The importance of identifying and validating prognostic factors in oncology.

@ast

The importance of identifying and validating prognostic factors in oncology.

@en

The importance of identifying and validating prognostic factors in oncology.

@nl

P1433

Q34090548-EAB71A63-AB42-4406-9340-9936B6F2FD43

P1476

Q34090548-7D54F97F-50E6-4231-845B-55EF5A804E39

P2093

Q34090548-7707D7F0-9396-405E-A7BD-4AA9B4EC5442

P2860

Q34090548-02E09E73-9AFA-4DA9-8218-40D4BADD1079

Q34090548-06DCDF76-62D1-46A3-8C55-7B33A42D1003

Q34090548-0EBEE091-944F-49F0-AB90-402606F1682B

Q34090548-1002AB6A-04B1-414F-8445-CA2C8EE0FD78

Q34090548-1E1F9FF3-94BF-4A6A-9F84-7F0D0B6A36E5

Q34090548-259768BF-1DCD-4EA7-91BB-5F1BD398FF7C

Q34090548-2629FE7C-7DF2-41E0-AD49-E6B609B385BC

Q34090548-548D9339-C8D0-488B-96A9-3E5A62C76DB6

Q34090548-57CD814B-88EB-43DF-BA7D-F7D49E223FBB

Q34090548-5B69F545-6775-4519-B5E3-0FA42CC3E461

P304

Q34090548-3B7D28F4-9DBC-4E86-86DD-30A19255A290

P31

Q34090548-0367B574-2BAE-485D-B14C-0009D1D2277D

P356

Q34090548-8486465B-8D5D-4663-9E71-C18201D7891A

P433

Q34090548-EF87A1C8-C20C-4126-8118-96810B971263

P478

Q34090548-B400166B-A0F8-46F1-999B-AE4BB746C833

P50

Q34090548-EDD79105-3428-4D16-9617-3C106E0D690A

P577

Q34090548-BF88432D-1500-4FA1-978F-D2D29BEEB124

P5875

Q34090548-AF912F6A-9067-41C2-B042-7DE47F2DA9D7

P698

Q34090548-1E995CBC-E9CD-4C1E-97EC-2237B71344CA

P932

Q34090548-BBD05CC9-887A-4F55-A159-6659A2D41A79

P356

J.SEMINONCOL.2010.04.001

P1433

Seminars in Oncology

P1476

The importance of identifying and validating prognostic factors in oncology

@en

P2093

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal data analysis for discrete and continuous outcomes

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

What do we mean by validating a prognostic model?

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Challenges in breast cancer clinical trial design in the postgenomic era.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

Tree-based model for breast cancer prognostication.

Statistical aspects of prognostic factor studies in oncology.

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

P304

e9-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMINONCOL.2010.04.001

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44622876

http://www.w3.org/2001/XMLSchema#string

P698

20494694

http://www.w3.org/2001/XMLSchema#string

P932

2929829

http://www.w3.org/2001/XMLSchema#string